Defective lysosomal arginine transport in juvenile Batten disease.
Mutations in the CLN3 gene, which encodes a lysosomal membrane protein, are responsible for the neurodegenerative disorder juvenile Batten disease. A previous study on the yeast homolog to CLN3, designated Btn1p, revealed a potential role for CLN3 in the transport of arginine into the yeast vacuole, the equivalent organelle to the mammalian lysosome. Lysosomes isolated from lymphoblast cell lines, established from individuals with juvenile Batten disease-bearing mutations in CLN3, but not age-matched controls, demonstrate defective transport of arginine. Furthermore, we show that there is a depletion of arginine in cells derived from individuals with juvenile Batten disease. We have, therefore, characterized lysosomal arginine transport in normal lysosomes and show that it is ATP-, v-ATPase- and cationic-dependent. This and previous studies have shown that both arginine and lysine are transported by the same transport system, designated system c. However, we report that lysosomes isolated from juvenile Batten disease lymphoblasts are only defective for arginine transport. These results suggest that the CLN3 defect in juvenile Batten disease may affect how intracellular levels of arginine are regulated or distributed throughout the cell. This assertion is supported by two other experimental approaches. First, an antibody to CLN3 can block lysosomal arginine transport and second, expression of CLN3 in JNCL cells using a lentiviral vector can restore lysosomal arginine transport. CLN3 may have a role in regulating intracellular levels of arginine possibly through control of the transport of this amino acid into lysosomes.
Ramirez-Montealegre
Denia
D
Center for Aging and Developmental Biology, Aab Institute of Biomedical Sciences, Rochester, NY 14642, USA.
Pearce
David A
DA
D000255:Adenosine Triphosphate / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D019138:Antibodies, Blocking / Q000494:pharmacology; D001120:Arginine / Q000172:deficiency / Q000378:metabolism*; D001692:Biological Transport / Q000235:genetics; D002412:Cations / Q000378:metabolism; D002648:Child; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D008247:Lysosomes / Q000378:metabolism*; D008297:Male; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D018832:Molecular Chaperones / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D009154:Mutation; D009472:Neuronal Ceroid-Lipofuscinoses / Q000235:genetics / Q000378:metabolism*; D025262:Vacuolar Proton-Translocating ATPases / Q000378:metabolism
D019138:Antibodies, Blocking; C105199:CLN3 protein, human; D002412:Cations; D008562:Membrane Glycoproteins; D018832:Molecular Chaperones; D000255:Adenosine Triphosphate; D001120:Arginine; D025262:Vacuolar Proton-Translocating ATPases